Document is current
Any future updates will be listed below
-
Authors
Runnebaum, Ingo B.
Kather, Angela
Goerdt, Clara Evangelia
Nguyen, Huyen Thi Thanh
Bokhua, Davit
-
Funding
Funding for this research was provided by:
Friedrich-Schiller-Universität Jena
- License Information
-
More Information
Article History
Received: 2 October 2025
Accepted: 1 March 2026
First Online: 12 April 2026
Disclosure
: The first author (IBR) is a founding member of the Ovarian Tumor Committee of the German Gynecologic Oncology Group (AGO) and a member of the author team releasing the “S3 Guideline on Diagnosis, Treatment, and Follow-up of Malignant Ovarian Tumours.” IBR is CEO and co-founder of RU21 GmbH (r-u-21.com), a company focused on longevity, prevention, and consumer healthcare. This role is independent of the research presented. The other authors declare no conflicts of interest. Institutional support; no external funding.
: This study was conducted in accordance with the Declaration of Helsinki and was approved by the ethics committee of the Jena University Hospital (no. 2021-2262-Daten on 09.06.2021)
: No identifying information is included in the manuscript. Analyses are exclusively based on data from clinical records, which in Germany are allowed to be used for research purposes by the attending clinic without explicit consent from the patient.
: Not commissioned, externally peer reviewed.
